Physician profile
Robert B Turnquist
NPI 1902829617
$2,978.53
in general payments reported to CMS, 2019-2025
36 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $95.71 · 2022: $260 · 2023: $523 · 2024: $724 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $667.83 | 2019-2025 | |
| Novo Nordisk INC | $399.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $297.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $151.48 | 2022-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $149.57 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.81 | 2024-2025 | Caplyta |
| Abbott Laboratories | $129.23 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Glaxosmithkline, LLC. | $104.89 | 2019-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $89.76 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $84.99 | 2022-2024 | Quviviq |
| Amgen INC. | $68.04 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $64.43 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Tempus Ai, INC | $47.51 | 2024 | |
| Sanofi-Aventis U.S. LLC | $47.26 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $44.28 | 2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Turnquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.